Radovan Vrhovac

Prof. Dr. Radovan Vrhovac

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
FBFrédéric Baron
Frédéric Baron
FEFabio Efficace
Fabio Efficace
LCLaura Cannella
Laura Cannella
PMPetra Muus
Petra Muus
STSilvia Maria Trisolini
Silvia Maria Trisolini
SSStefan Suciu
Stefan Suciu

6 December 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
FBFrédéric Baron
Frédéric Baron
Marian J.P.L. Stevens-KroefMarian J.P.L. Stevens-Kroef
Marian J.P.L. Stevens-Kroef
MKMichal Kicinski
Michal Kicinski
GMGiovanna Meloni
Giovanna Meloni
PMPetra Muus
Petra Muus
SSStefan Suciu
Stefan Suciu
Monosomal karyotype (MK) confers a poor prognosis in patients with acute myeloid leukemia (AML). Here, we determined the impact of the type of remission-induction chemotherapy and the impact of having a donor in younger AML patients with a MK included in two phase III trials. In the first trial, patients were randomized to receive either daunorubicin (DNR), mitoxantrone (MTX), or idarubicin (IDA) in addition to standard-dose cytarabine (SDAC) and etoposide for induction chemotherapy. In the second trial, patients were randomized between either SDAC or high dose cytarabine (HiDAC) induction, both with DNR and etoposide. In both trials, patients who achieved a complete remission with (CR) or without (CRi) complete hematological recovery received an allogeneic hematopoietic stem cell transplantation (allo-HSCT) if they had a donor or an autologous HSCT (auto-HSCT) otherwise. In comparison to patients with intermediate risk cytogenetics without MK (n=1584) and with adverse cytogenetics without MK (n=218), MK+ patients (n=188) were more likely not to achieve a CR/CRi (odds ratio=2.85, 95% confidence interval, CI: 2.10-3.88) and had shorter overall survival (OS) (hazard ratio, HR=2.44, 95% CI: 2.08-2.88) and OS from CR/CRi (HR=2.73, 95% CI: 2.17-3.45). There was no impact of the type of anthracycline or of SDAC vs HiDAC on outcomes in MK+ patients. Among MK+ patients who achieved a CR/CRi, HLA-identical related donor availability was associated with longer survival from CR/CRi (HR=0.59, 95% CI: 0.37-0.95). In summary, these data suggest no benefit of HiDAC in MK+ patients but better OS associated with allo-HSCT.

1 November 2017 in Human Immunology
Verified
Journal Article
Closed access
MKMarija Burek Kamenaric
Marija Burek Kamenaric
MMMarija Maskalan
Marija Maskalan
ZGZorana Grubic
Zorana Grubic
MMMirta Mikulic
Mirta Mikulic
RSRanka Serventi Seiwerth
Ranka Serventi Seiwerth
RŽRenata Žunec
Renata Žunec

1 June 2010
Verified
Journal Article
Closed access
DRDelfa Radić-Kristo
Delfa Radić-Kristo
APAna Planinc-Peraica
Ana Planinc-Peraica
SOSlobodanka Ostojić
Slobodanka Ostojić
RVRadovan Vrhovac
Radovan Vrhovac
IKIka Kardum-Skelin
Ika Kardum-Skelin
BJBranimir Jaksić
Branimir Jaksić

1 March 2010
Verified
Journal Article
Closed access
NSNives Dzeko Skugor
Nives Dzeko Skugor
ZPZinaida Perić
Zinaida Perić
RVRadovan Vrhovac
Radovan Vrhovac
DRDelfa Radić-Kristo
Delfa Radić-Kristo
IKIka Kardum-Skelin
Ika Kardum-Skelin
BJBranimir Jaksić
Branimir Jaksić

1 September 2011
Verified
Journal Article
Closed access
NGNjetocka Gredelj-Simec
Njetocka Gredelj-Simec
BJBiljana Jelić-Puskarić
Biljana Jelić-Puskarić
AOAlen Ostojić
Alen Ostojić
ZSZoran Siftar
Zoran Siftar
DFDunja Fiala
Dunja Fiala
BJBranimir Jaksić
Branimir Jaksić